S&P 500   4,566.48 (+0.47%)
DOW   35,741.15 (+0.18%)
QQQ   377.90 (+1.02%)
AAPL   148.50 (-0.13%)
MSFT   307.85 (-0.42%)
FB   328.37 (+1.16%)
GOOGL   2,749.78 (-0.06%)
TSLA   1,022.89 (+12.45%)
AMZN   3,318.00 (-0.53%)
NVDA   231.28 (+1.77%)
BABA   176.03 (-0.94%)
NIO   41.15 (+5.84%)
CGC   13.56 (+1.35%)
GE   105.28 (+1.18%)
AMD   122.31 (+2.08%)
MU   68.66 (+1.70%)
T   25.60 (+0.43%)
F   16.00 (-1.72%)
ACB   7.18 (+1.56%)
DIS   172.04 (+1.55%)
PFE   43.15 (-0.02%)
BA   212.86 (-0.05%)
AMC   36.79 (+0.52%)
S&P 500   4,566.48 (+0.47%)
DOW   35,741.15 (+0.18%)
QQQ   377.90 (+1.02%)
AAPL   148.50 (-0.13%)
MSFT   307.85 (-0.42%)
FB   328.37 (+1.16%)
GOOGL   2,749.78 (-0.06%)
TSLA   1,022.89 (+12.45%)
AMZN   3,318.00 (-0.53%)
NVDA   231.28 (+1.77%)
BABA   176.03 (-0.94%)
NIO   41.15 (+5.84%)
CGC   13.56 (+1.35%)
GE   105.28 (+1.18%)
AMD   122.31 (+2.08%)
MU   68.66 (+1.70%)
T   25.60 (+0.43%)
F   16.00 (-1.72%)
ACB   7.18 (+1.56%)
DIS   172.04 (+1.55%)
PFE   43.15 (-0.02%)
BA   212.86 (-0.05%)
AMC   36.79 (+0.52%)
S&P 500   4,566.48 (+0.47%)
DOW   35,741.15 (+0.18%)
QQQ   377.90 (+1.02%)
AAPL   148.50 (-0.13%)
MSFT   307.85 (-0.42%)
FB   328.37 (+1.16%)
GOOGL   2,749.78 (-0.06%)
TSLA   1,022.89 (+12.45%)
AMZN   3,318.00 (-0.53%)
NVDA   231.28 (+1.77%)
BABA   176.03 (-0.94%)
NIO   41.15 (+5.84%)
CGC   13.56 (+1.35%)
GE   105.28 (+1.18%)
AMD   122.31 (+2.08%)
MU   68.66 (+1.70%)
T   25.60 (+0.43%)
F   16.00 (-1.72%)
ACB   7.18 (+1.56%)
DIS   172.04 (+1.55%)
PFE   43.15 (-0.02%)
BA   212.86 (-0.05%)
AMC   36.79 (+0.52%)
S&P 500   4,566.48 (+0.47%)
DOW   35,741.15 (+0.18%)
QQQ   377.90 (+1.02%)
AAPL   148.50 (-0.13%)
MSFT   307.85 (-0.42%)
FB   328.37 (+1.16%)
GOOGL   2,749.78 (-0.06%)
TSLA   1,022.89 (+12.45%)
AMZN   3,318.00 (-0.53%)
NVDA   231.28 (+1.77%)
BABA   176.03 (-0.94%)
NIO   41.15 (+5.84%)
CGC   13.56 (+1.35%)
GE   105.28 (+1.18%)
AMD   122.31 (+2.08%)
MU   68.66 (+1.70%)
T   25.60 (+0.43%)
F   16.00 (-1.72%)
ACB   7.18 (+1.56%)
DIS   172.04 (+1.55%)
PFE   43.15 (-0.02%)
BA   212.86 (-0.05%)
AMC   36.79 (+0.52%)
NYSE:PBH

Prestige Consumer Healthcare Stock Forecast, Price & News

$60.01
+0.79 (+1.33 %)
(As of 10/25/2021 03:58 PM ET)
Add
Compare
Today's Range
$58.54
$60.08
50-Day Range
$52.54
$60.54
52-Week Range
$32.19
$60.57
Volume6,169 shs
Average Volume340,430 shs
Market Capitalization$3.00 billion
P/E Ratio17.00
Dividend YieldN/A
Beta0.69
30 days | 90 days | 365 days | Advanced Chart
Receive PBH News and Ratings via Email

Sign-up to receive the latest news and ratings for Prestige Consumer Healthcare and its competitors with MarketBeat's FREE daily newsletter.


Prestige Consumer Healthcare logo

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American OTC Healthcare and International OTC Healthcare. The North American and International OTC Healthcare segments manages the following brands: BC/Goody's, Beano, Boudreaux's Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden's, Monistat, Nix, Pedia-Lax, and Summer's Eve. The company was founded in 1996 and is headquartered in Tarrytown, NY.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Personal Products
CUSIP
74112D10
Employees
505
Year Founded
N/A

Sales & Book Value

Annual Sales
$943.36 million
Cash Flow
$4.48 per share
Book Value
$27.24 per share

Profitability

Net Income
$164.68 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$3.00 billion
Next Earnings Date
11/4/2021 (Confirmed)
Optionable
Optionable

MarketRank

Overall MarketRank

1.85 out of 5 stars

Consumer Discretionary Sector

218th out of 385 stocks

Pharmaceutical Preparations Industry

354th out of 667 stocks

Analyst Opinion: 3.2Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -












Prestige Consumer Healthcare (NYSE:PBH) Frequently Asked Questions

Is Prestige Consumer Healthcare a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Prestige Consumer Healthcare stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PBH, but not buy additional shares or sell existing shares.
View analyst ratings for Prestige Consumer Healthcare
or view top-rated stocks.

What stocks does MarketBeat like better than Prestige Consumer Healthcare?

Wall Street analysts have given Prestige Consumer Healthcare a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Prestige Consumer Healthcare wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Prestige Consumer Healthcare's next earnings date?

Prestige Consumer Healthcare is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Prestige Consumer Healthcare
.

How can I listen to Prestige Consumer Healthcare's earnings call?

Prestige Consumer Healthcare will be holding an earnings conference call on Thursday, November 4th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "7261575".

How were Prestige Consumer Healthcare's earnings last quarter?

Prestige Consumer Healthcare Inc. (NYSE:PBH) issued its quarterly earnings data on Thursday, August, 5th. The company reported $1.14 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.87 by $0.27. The business had revenue of $269.10 million for the quarter, compared to analyst estimates of $232.41 million. Prestige Consumer Healthcare had a net margin of 18.18% and a trailing twelve-month return on equity of 13.25%. The company's quarterly revenue was up 17.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.86 earnings per share.
View Prestige Consumer Healthcare's earnings history
.

How has Prestige Consumer Healthcare's stock been impacted by COVID-19 (Coronavirus)?

Prestige Consumer Healthcare's stock was trading at $35.91 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PBH shares have increased by 66.3% and is now trading at $59.73.
View which stocks have been most impacted by COVID-19
.

What guidance has Prestige Consumer Healthcare issued on next quarter's earnings?

Prestige Consumer Healthcare updated its FY 2022 earnings guidance on Thursday, September, 2nd. The company provided earnings per share (EPS) guidance of $3.900-$ for the period, compared to the Thomson Reuters consensus EPS estimate of $3.610. The company issued revenue guidance of $1.05 B-, compared to the consensus revenue estimate of $969.54 million.

What price target have analysts set for PBH?

5 brokerages have issued 1 year target prices for Prestige Consumer Healthcare's shares. Their forecasts range from $61.00 to $125.00. On average, they anticipate Prestige Consumer Healthcare's stock price to reach $107.40 in the next year. This suggests a possible upside of 79.8% from the stock's current price.
View analysts' price targets for Prestige Consumer Healthcare
or view top-rated stocks among Wall Street analysts.

Who are Prestige Consumer Healthcare's key executives?

Prestige Consumer Healthcare's management team includes the following people:
  • Ronald M. Lombardi, Chairman, President & Chief Executive Officer
  • Jeff Zerillo, Senior Vice President-Operations
  • Christine Sacco, Chief Financial Officer
  • William C. P'Pool, Secretary, Senior Vice President & General Counsel
  • Adel Mekhail, Executive Vice President-Marketing & Sales

What is Ronald M. Lombardi's approval rating as Prestige Consumer Healthcare's CEO?

8 employees have rated Prestige Consumer Healthcare CEO Ronald M. Lombardi on Glassdoor.com. Ronald M. Lombardi has an approval rating of 61% among Prestige Consumer Healthcare's employees. This puts Ronald M. Lombardi in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Prestige Consumer Healthcare's key competitors?

What other stocks do shareholders of Prestige Consumer Healthcare own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Pfizer (PFE), AbbVie (ABBV), Gilead Sciences (GILD), AT&T (T), Intel (INTC), ONEOK (OKE), Wells Fargo & Company (WFC), International Business Machines (IBM), Micron Technology (MU) and Teva Pharmaceutical Industries (TEVA).

What is Prestige Consumer Healthcare's stock symbol?

Prestige Consumer Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBH."

Who are Prestige Consumer Healthcare's major shareholders?

Prestige Consumer Healthcare's stock is owned by a number of retail and institutional investors. Top institutional shareholders include North Star Asset Management Inc. (0.50%), Wedge Capital Management L L P NC (0.39%), Foundry Partners LLC (0.34%), Robeco Institutional Asset Management B.V. (0.31%), Hillsdale Investment Management Inc. (0.18%) and New York State Teachers Retirement System (0.13%). Company insiders that own Prestige Consumer Healthcare stock include Mary Beth Fritz, Paton Brett and Ronald M Lombardi.
View institutional ownership trends for Prestige Consumer Healthcare
.

Which institutional investors are selling Prestige Consumer Healthcare stock?

PBH stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, Wedge Capital Management L L P NC, Exchange Traded Concepts LLC, CHICAGO TRUST Co NA, and Crossmark Global Holdings Inc..
View insider buying and selling activity for Prestige Consumer Healthcare
or view top insider-selling stocks.

Which institutional investors are buying Prestige Consumer Healthcare stock?

PBH stock was bought by a variety of institutional investors in the last quarter, including Foundry Partners LLC, Robeco Institutional Asset Management B.V., Strs Ohio, Hillsdale Investment Management Inc., Everence Capital Management Inc., Ritholtz Wealth Management, State of Alaska Department of Revenue, and North Star Asset Management Inc..
View insider buying and selling activity for Prestige Consumer Healthcare
or or view top insider-buying stocks.

How do I buy shares of Prestige Consumer Healthcare?

Shares of PBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Prestige Consumer Healthcare's stock price today?

One share of PBH stock can currently be purchased for approximately $59.73.

How much money does Prestige Consumer Healthcare make?

Prestige Consumer Healthcare has a market capitalization of $2.99 billion and generates $943.36 million in revenue each year. The company earns $164.68 million in net income (profit) each year or $3.24 on an earnings per share basis.

How many employees does Prestige Consumer Healthcare have?

Prestige Consumer Healthcare employs 505 workers across the globe.

What is Prestige Consumer Healthcare's official website?

The official website for Prestige Consumer Healthcare is www.prestigebrands.com.

Where are Prestige Consumer Healthcare's headquarters?

Prestige Consumer Healthcare is headquartered at 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591.

How can I contact Prestige Consumer Healthcare?

Prestige Consumer Healthcare's mailing address is 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591. The company can be reached via phone at (914) 524-6800 or via email at [email protected].


This page was last updated on 10/25/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.